Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market
完整報告名稱與涵蓋範圍
Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Size, Share & Trends Analysis Report, By Technology (Self-Amplifying and Trans-Amplifying RNA, Circular RNA, Engineered UTRs, Codon Optimization and Novel Modifications, Next-Generation Delivery and Targeted LNPs, In Vivo Cell Engineering and Editing Payloads), By Application (Infectious Disease Vaccines, Oncology, Rare Disease and Protein Replacement, Autoimmune, Cardiometabolic and Other Chronic Diseases), By Development Stage (Preclinical, Clinical, Approved), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The next-generation mRNA therapeutics and vaccines market, often termed mRNA 2.0, covers products built on advances beyond first-generation linear modified mRNA, including self-amplifying and trans-amplifying RNA, circular RNA, engineered untranslated regions and novel chemistries, targeted and next-generation delivery systems and payloads that engineer cells in vivo, across vaccines, oncology, rare disease and chronic conditions. First-generation mRNA products and dedicated studies on self-amplifying and circular RNA are referenced but excluded from double counting; this study aggregates the next-generation pipeline and its competitive landscape.
The first approved self-amplifying vaccine demonstrated that lower doses can deliver durable immunity, and developers are now pursuing longer expression, tissue-selective delivery, programmable control of expression and reduced reactogenicity to expand mRNA from vaccines into chronic therapeutics. Large pharmaceutical companies have acquired or licensed circular RNA and delivery platforms, while pioneers reinvest pandemic-era capital into platform upgrades. Commercial revenue in the forecast depends on approval timing for next-generation constructs, on demonstrated differentiation over first-generation products and on manufacturing readiness for longer and structurally different RNAs.
North America, Europe and Japan lead development, with China contributing self-amplifying and circular RNA innovators. Competition involves mRNA pioneers, platform-focused biotechnology companies and pharmaceutical groups building next-generation portfolios through acquisitions.
The InsightAce study provides US$ revenue forecasts for every technology, application, development stage and end user and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Snapshot
Chapter 4. Global Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Technology Estimates & Trend Analysis
5.1. Technology & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Technology:
5.2.1. Self-Amplifying and Trans-Amplifying RNA
5.2.2. Circular RNA
5.2.3. Engineered UTRs, Codon Optimization and Novel Modifications
5.2.4. Next-Generation Delivery and Targeted LNPs
5.2.5. In Vivo Cell Engineering and Editing Payloads
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. Application & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
6.2.1. Infectious Disease Vaccines
6.2.2. Oncology
6.2.3. Rare Disease and Protein Replacement
6.2.4. Autoimmune, Cardiometabolic and Other Chronic Diseases
Chapter 7. Market Segmentation 3: By Development Stage Estimates & Trend Analysis
7.1. Development Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
7.2.1. Preclinical
7.2.2. Clinical
7.2.3. Approved
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals and Treatment Centers
8.2.2. Vaccination Programs and Clinics
Chapter 9. Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Moderna, Inc.
11.2. BioNTech SE
11.3. Arcturus Therapeutics Holdings Inc.
11.4. Orna Therapeutics (Eli Lilly and Company)
11.5. Strand Therapeutics, Inc.
11.6. ReCode Therapeutics, Inc.
11.7. Sail Biomedicines
11.8. Replicate Bioscience, Inc.
11.9. Sanofi
11.10. CSL Seqirus
11.11. Pfizer Inc.
11.12. AstraZeneca plc
11.13. Gritstone Legacy Platforms
11.14. Chimeron Bio
11.15. Ziphius Vaccines
圖表清單 List of Tables & Figures
Table 1. Global Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Revenue Forecast by Technology, 2026-2035 (US$ Mn)
Figure 1. Global Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Segmentation Overview
Table 2. Global Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 2. Global Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Share by Technology, 2026 & 2035
Table 3. Global Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 3. Next-Generation RNA Technology Landscape and Differentiation Versus First-Generation mRNA
Table 4. Global Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Global Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Share by Application, 2026 & 2035
Table 5. North America Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Clinical Pipeline of Next-Generation Constructs by Application and Phase, 2026
Table 6. Europe Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Growth Opportunity Analysis
Table 7. Asia Pacific Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Platform Acquisition and Licensing Activity in Next-Generation RNA, 2022-2026
Table 8. Latin America Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Participants
Table 9. Middle East & Africa Next-Generation mRNA Therapeutics & Vaccines (mRNA 2.0) Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們